SCOPUS 정보 검색 플랫폼

Volumn 219, Issue 4, 2012, Pages 959-970

Effects of a novel mGlu 2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

(13) Lowe, Stephen a Dean, Robert b Ackermann, Bradley b Jackson, Kimberley b Natanegara, Fanni b Anderson, Shelby b Eckstein, James b Yuen, Eunice b Ayan Oshodi, Mosun b Ho, Mary a McKinzie, David b Perry, Kenneth b Svensson, Kjell b

a NATIONAL UNIVERSITY OF SINGAPORE (Singapore)

b ELI LILLY AND COMPANY (United States)

Author keywords

Cerebrospinal fluid; CNS pharmacodynamics; Dopamine; Glutamate; mGlu2,3 agonists; Serotonin

Indexed keywords

4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; MONOAMINE; NORADRENALIN; PLACEBO; POMAGLUMETAD METHIONIL; SEROTONIN;

ADULT; AMNESIA; ANIMAL EXPERIMENT; ARTICLE; BLEPHAROSPASM; CEREBROSPINAL FLUID; COLD SWEAT; CONTROLLED STUDY; DIZZINESS; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; ERUCTATION; FATIGUE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INSOMNIA; MALE; MICRODIALYSIS; MONOAMINE METABOLISM; NAUSEA; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SEROTONIN METABOLISM; SINGLE BLIND PROCEDURE; VOMITING;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOMARKERS, PHARMACOLOGICAL; CYCLIC S-OXIDES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SEROTONIN; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84856675210 PISSN: 00333158 EISSN: 14322072 Source Type: Journal
DOI: 10.1007/s00213-011-2427-9 Document Type: Article

Times cited : (16)

References (14)

1
- 0033842964
- Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: Investigations into possible mechanism of action in vivo
- 2/3 receptor agonist: investigations into possible mechanism of action in vivo J Pharmacol Exp Ther 294 800 809 10945827 1:CAS:528:DC%2BD3cXmtFCnsLk%3D (Pubitemid 30666827)
- (2000) Journal of Pharmacology and Experimental Therapeutics , vol.294 , Issue.3 , pp. 800-809
- Bond, A.¹ Jones, N.M.² Hicks, C.A.³ Whiffin, G.M.⁴ Ward, M.A.⁵ O'Neill, M.F.⁶ Kingston, A.E.⁷ Monn, J.A.⁸ Ornstein, P.L.⁹ Schoepp, D.D.¹⁰ Lodge, D.¹¹ O'Neill, M.J.¹²

2
- 0034852645
- Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs
- V Bruno G Battaglia A Copani M D'Onofrio IP Di BA De D Melchiorri PJ Flor F Nicoletti 2001 Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs J Cerebr Blood Flow Metabol 21 1013 1033 10.1097/00004647-200109000-00001 1:CAS:528:DC%2BD3MXnt1Snu74%3D (Pubitemid 32823739)
- (2001) Journal of Cerebral Blood Flow and Metabolism , vol.21 , Issue.9 , pp. 1013-1033
- Bruno, V.¹ Battaglia, G.² Copani, A.³ D'Onofrio, M.⁴ Di Iorio, P.⁵ De Blasi, A.⁶ Melchiorri, D.⁷ Flor, P.J.⁸ Nicoletti, F.⁹

3
- 0033844761
- The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat
- DOI 10.1046/j.1471-4159.2000.0751147.x
- 2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat J Neurochem 75 1147 1154 10936197 10.1046/j.1471-4159.2000.0751147.x 1:CAS:528:DC%2BD3cXmtFyrs7k%3D (Pubitemid 30660504)
- (2000) Journal of Neurochemistry , vol.75 , Issue.3 , pp. 1147-1154
- Cartmell, J.¹ Perry, K.W.² Salhoff, C.R.³ Monn, J.A.⁴ Schoepp, D.D.⁵

4
- 0003484310
- CDER (Center for Drug Evaluation and Research)
- CDER (Center for Drug Evaluation and Research) (2001) Guidance for industry: bioanalytical method validation
- (2001) Guidance for Industry: Bioanalytical Method Validation

5
- 43649087034
- Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder
- DOI 10.1038/sj.npp.1301531, PII 1301531
- 2/3 agonist in the treatment of generalized anxiety disorder Neuropsychopharmacology 33 1603 1610 17712352 10.1038/sj.npp.1301531 1:CAS:528:DC%2BD1cXlvVSrtrk%3D (Pubitemid 351684700)
- (2008) Neuropsychopharmacology , vol.33 , Issue.7 , pp. 1603-1610
- Dunayevich, E.¹ Erickson, J.² Levine, L.³ Landbloom, R.⁴ Schoepp, D.D.⁵ Tollefson, G.D.⁶

6
- 46849090753
- Simultaneous profiling of multiple neurochemical pathways from a single cerebrospinal fluid sample using GC/MS/MS with electron capture detection
- DOI 10.1002/jms.1376
- JA Eckstein GM Ammerman JM Reveles BL Ackermann 2008 Simultaneous profiling of multiple neurochemical pathways from a single cerebrospinal fluid sample using GC/MS/MS with electron capture detection J Mass Spectrom 43 782 790 18286669 10.1002/jms.1376 1:CAS:528:DC%2BD1cXnvFClsr0%3D (Pubitemid 351954812)
- (2008) Journal of Mass Spectrometry , vol.43 , Issue.6 , pp. 782-790
- Eckstein, J.A.¹ Ammerman, G.M.² Reveles, J.M.³ Ackermann, B.L.⁴

7
- 45749139623
- Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6- dicarboxylic acid (LY404039)
- DOI 10.1124/jpet.108.136861
- 2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) J Pharmacol Exp Ther 326 209 217 18424625 10.1124/jpet.108.136861 1:CAS:528:DC%2BD1cXotlyltrw%3D (Pubitemid 351872145)
- (2008) Journal of Pharmacology and Experimental Therapeutics , vol.326 , Issue.1 , pp. 209-217
- Fell, M.J.¹ Svensson, K.A.² Johnson, B.G.³ Schoepp, D.D.⁴

8
- 77954094209
- 2/3 receptor for the treatment of schizophrenia
- 10.1016/j.schres.2010.02.679
- 2/3 receptor for the treatment of schizophrenia Schizophr Res 117 379 10.1016/j.schres.2010.02.679
- (2010) Schizophr Res , vol.117 , pp. 379
- Kinon, B.J.¹ Zhang, L.² Williams, J.E.³ Osuntokun, O.O.⁴ Millen, B.A.⁵ Kollack-Walker, S.⁶

9
- 0031933103
- Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
- DOI 10.1007/s002130050551
- XM Li KW Perry DT Wong FP Bymaster 1998 Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum Psychopharmacology (Berl) 136 153 161 10.1007/s002130050551 1:CAS:528:DyaK1cXisFGitb8%3D (Pubitemid 28137955)
- (1998) Psychopharmacology , vol.136 , Issue.2 , pp. 153-161
- Li, X.-M.¹ Perry, K.W.² Wong, D.T.³ Bymaster, F.P.⁴

10
- 33846458648
- Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: Identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors
- DOI 10.1021/jm060917u
- 2/3 receptors J Med Chem 50 233 240 17228865 10.1021/jm060917u 1:CAS:528: DC%2BD28XhtlCit73P (Pubitemid 46147704)
- (2007) Journal of Medicinal Chemistry , vol.50 , Issue.2 , pp. 233-240
- Monn, J.A.¹ Massey, S.M.² Valli, M.J.³ Henry, S.S.⁴ Stephenson, G.A.⁵ Bures, M.⁶ Herin, M.⁷ Catlow, J.⁸ Giera, D.⁹ Wright, R.A.¹⁰ Johnson, B.G.¹¹ Andis, S.L.¹² Kingston, A.¹³ Schoepp, D.D.¹⁴

11
- 33947610531
- Identifying pharmacodynamic protein markers of centrally active drugs in humans: A pilot study in a novel clinical model
- DOI 10.1021/pr0603710
- ST Patil RE Higgs JE Brandt MD Knierman V Gelfanova JP Butler AM Downing J Dorocke RA Dean WZ Potter D Michelson AX Pan SS Jhee JE Hale 2007 Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model J Proteome Res 6 955 966 17243662 10.1021/pr0603710 1:CAS:528:DC%2BD2sXns1ygsw%3D%3D (Pubitemid 46480460)
- (2007) Journal of Proteome Research , vol.6 , Issue.3 , pp. 955-966
- Patil, S.T.¹ Higgs, R.E.² Brandt, J.E.³ Knierman, M.D.⁴ Gelfanova, V.⁵ Butler, J.P.⁶ Downing, A.M.⁷ Dorocke, J.⁸ Dean, R.A.⁹ Potter, W.Z.¹⁰ Michelson, D.¹¹ Pan, A.X.¹² Jhee, S.S.¹³ Hale, J.E.¹⁴

12
- 34948858402
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial
- DOI 10.1038/nm1632, PII NM1632
- 2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat Med 13 1102 1107 17767166 10.1038/nm1632 1:CAS:528:DC%2BD2sXhtVSgtrvF (Pubitemid 47517511)
- (2007) Nature Medicine , vol.13 , Issue.9 , pp. 1102-1107
- Patil, S.T.¹ Zhang, L.² Martenyi, F.³ Lowe, S.L.⁴ Jackson, K.A.⁵ Andreev, B.V.⁶ Avedisova, A.S.⁷ Bardenstein, L.M.⁸ Gurovich, I.Y.⁹ Morozova, M.A.¹⁰ Mosolov, S.N.¹¹ Neznanov, N.G.¹² Reznik, A.M.¹³ Smulevich, A.B.¹⁴ Tochilov, V.A.¹⁵ Johnson, B.G.¹⁶ Monn, J.A.¹⁷ Schoepp, D.D.¹⁸

13
- 0003717437
- Academic Sydney
- Paxinos G, Watson C (1986) The rat brain in stereotoxic coordinates. Academic, Sydney
- (1986) The Rat Brain in Stereotoxic Coordinates
- Paxinos, G.¹ Watson, C.²

14
- 34250162538
- In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
- DOI 10.1007/s00213-007-0758-3
- 2/3 receptor agonist LY404039 in animal models of psychiatric disorders Psychopharmacology (Berl) 193 121 136 10.1007/s00213-007-0758-3 1:CAS:528:DC%2BD2sXmtlGktr8%3D (Pubitemid 46906627)
- (2007) Psychopharmacology , vol.193 , Issue.1 , pp. 121-136
- Rorick-Kehn, L.M.¹ Johnson, B.G.² Knitowski, K.M.³ Salhoff, C.R.⁴ Witkin, J.M.⁵ Perry, K.W.⁶ Griffey, K.I.⁷ Tizzano, J.P.⁸ Monn, J.A.⁹ McKinzie, D.L.¹⁰ Schoepp, D.D.¹¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.